StockData
PharmaCyte Biotech, Inc. logo

PharmaCyte Biotech, Inc. (PMCB) stock

PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 7/30
$5.42−0.15 (-2.69%)

Close on Nov 17, 2026Market cap $58.19MP/E –Yield –

PharmaCyte Biotech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

PharmaCyte Biotech's operating income for the twelve months ending Apr 30, 2026 was -$6.85M. For fiscal 2026 it was -$6.85M. The highest annual figure on record is -$1.68M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2026Apr 30, 2026-$6.85M–
FY2025Apr 30, 2025-$4.38M–
FY2024Apr 30, 2024-$8.52M–
FY2023Apr 30, 2023-$6.46M–
FY2022Apr 30, 2022-$4.39M–
FY2021Apr 30, 2021-$3.62M–
FY2020Apr 30, 2020-$3.83M–
FY2019Apr 30, 2019-$4.10M–
FY2018Apr 30, 2018-$6.98M–
FY2017Apr 30, 2017-$4.44M–
FY2016Apr 30, 2016-$6.07M–
FY2015Apr 30, 2015-$13.26M–
FY2014Apr 30, 2014-$18.98M–
FY2013Apr 30, 2013-$1.68M–
FY2012Apr 30, 2012-$1.95M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026-$1.01M–
Q4 FY2026CQ1 2026Apr 30, 2026-$2.51M–
Q3 FY2026CQ4 2025Jan 31, 2026-$2.12M–
Q4 FY2025CQ1 2025Apr 30, 2025-$1.04M–
Q3 FY2025CQ4 2024Jan 31, 2025-$960.25K–
Q2 FY2025CQ3 2024Oct 31, 2024-$1.11M–
Q1 FY2025CQ2 2024Jul 31, 2024-$1.27M–
Q4 FY2024CQ1 2024Apr 30, 2024-$3.17M–
Q3 FY2024CQ4 2023Jan 31, 2024-$1.87M–
Q2 FY2024CQ3 2023Oct 31, 2023-$1.41M–
Q1 FY2024CQ2 2023Jul 31, 2023-$2.08M–
Q4 FY2023CQ1 2023Apr 30, 2023-$903.28K–
Q3 FY2023CQ4 2022Jan 31, 2023-$1.55M–
Q2 FY2023CQ3 2022Oct 31, 2022-$2.32M–
Q1 FY2023CQ2 2022Jul 31, 2022-$1.68M–
Q4 FY2022CQ1 2022Apr 30, 2022-$1.51M–
Q3 FY2022CQ4 2021Jan 31, 2022-$856.12K–
Q2 FY2022CQ3 2021Oct 31, 2021-$1.00M–
Q1 FY2022CQ2 2021Jul 31, 2021-$1.02M–
Q4 FY2021CQ1 2021Apr 30, 2021-$1.03M–
Q3 FY2021CQ4 2020Jan 31, 2021-$756.85K–
Q2 FY2021CQ3 2020Oct 31, 2020-$949.52K–
Q1 FY2021CQ2 2020Jul 31, 2020-$881.68K–
Q4 FY2020CQ1 2020Apr 30, 2020-$749.89K–
Q3 FY2020CQ4 2019Jan 31, 2020-$875.31K–
Q2 FY2020CQ3 2019Oct 31, 2019-$1.07M–
Q1 FY2020CQ2 2019Jul 31, 2019-$1.13M–
Q4 FY2019CQ1 2019Apr 30, 2019-$1.17M–
Q3 FY2019CQ4 2018Jan 31, 2019-$676.35K–
Q2 FY2019CQ3 2018Oct 31, 2018-$1.04M–
Q1 FY2019CQ2 2018Jul 31, 2018-$1.22M–
Q4 FY2018CQ1 2018Apr 30, 2018-$1.45M–
Q3 FY2018CQ4 2017Jan 31, 2018-$2.03M–
Q2 FY2018CQ3 2017Oct 31, 2017-$1.81M–
Q1 FY2018CQ2 2017Jul 31, 2017-$1.69M–
Q4 FY2017CQ1 2017Apr 30, 2017-$1.15M–
Q3 FY2017CQ4 2016Jan 31, 2017-$1.28M–
Q2 FY2017CQ3 2016Oct 31, 2016-$974.20K–
Q1 FY2017CQ2 2016Jul 31, 2016-$1.03M–

More PharmaCyte Biotech figures

See a number that looks wrong?